McIntyre David 4
4 · Inhibikase Therapeutics, Inc. · Filed Apr 16, 2025
Insider Transaction Report
Form 4
McIntyre David
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-04-14+1,775,539→ 1,775,539 totalExercise: $2.00Exp: 2035-04-14→ Common Stock (1,775,539 underlying)
Footnotes (1)
- [F1]25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date.